RESEARCH MONOGRAPH · KDC-MN-1311
Ropivacaine
Ropivacaine (Naropin) is a single-(S)-enantiomer amide local anesthetic approved in 1996, structurally intermediate between mepivacaine (propyl, racemic) and bupivacaine (butyl, racemic). It carries the propyl chain like mepivacaine but the (S)-only purity of the modern enantiopure agents. The shorter alkyl chain reduces lipid solubility versus bupivacaine, producing the so-called motor-sparing profile: at concentrations giving equivalent sensory block, motor block is less profound. That property drives selection in obstetric epidural where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor recovery before discharge matters. Cardiotoxicity profile is favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Amide local anesthetic (S-enantiomer propyl analog)
The (S)-propyl analog of bupivacaine and mepivacaine, marketed as Naropin, with reduced cardiotoxicity and motor-sparing sensory block profile.
Abstract
Ropivacaine ((S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 84057-95-4; molecular formula C17H26N2O; molecular weight 274.40) is an amide local anesthetic developed at AB Astra in the 1990s and approved by the FDA in 1996 (Naropin). The compound is structurally intermediate between mepivacaine (propyl chain, racemic) and bupivacaine (butyl chain, racemic): ropivacaine carries the propyl substituent like mepivacaine but is sold as a single (S)-enantiomer. The shorter alkyl chain reduces lipid solubility relative to bupivacaine, contributing to a less profound motor block at concentrations producing equivalent sensory block (the so-called motor-sparing property exploited in obstetric epidural analgesia and ambulatory regional anesthesia). The (S)-enantiomer purity confers a cardiotoxicity profile favorable to racemic bupivacaine, similar in magnitude to the levobupivacaine advantage. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Onset is 5 to 15 minutes for infiltration and peripheral nerve block; duration is 3 to 6 hours, generally somewhat shorter than bupivacaine at equivalent concentrations. The motor-sparing profile drives ropivacaine selection in obstetric epidural analgesia where ambulation during labor is desired, and in ambulatory peripheral nerve block where motor function recovery before discharge is operationally important. Lipid emulsion rescue applies to any LAST event with ropivacaine as for other long-acting amides.
Mechanism of action
Voltage-gated sodium channel block, state-dependent. Reduced lipid solubility versus bupivacaine drives motor-sparing sensory block characteristic.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Markham A, Faulds D. Ropivacaine: a review. Drugs 1996.
- Hansen TG. Ropivacaine: a pharmacological review. Expert Rev Neurother 2004.
- Knudsen K, et al. CNS and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo. Br J Anaesth 1997.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.